Immunic (NASDAQ:IMUX) Earns Outperform Rating from Analysts at William Blair

Research analysts at William Blair began coverage on shares of Immunic (NASDAQ:IMUX) in a research note issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating on the stock. William Blair also issued estimates for Immunic’s FY2025 earnings at ($0.89) EPS.

IMUX has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a report on Wednesday, February 26th. Finally, StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

NASDAQ IMUX opened at $1.20 on Tuesday. The company has a market capitalization of $108.09 million, a price-to-earnings ratio of -0.98 and a beta of 1.89. The stock has a 50-day moving average of $1.07 and a 200 day moving average of $1.21. Immunic has a one year low of $0.92 and a one year high of $2.11.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently modified their holdings of IMUX. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. State Street Corp lifted its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the period. Virtu Financial LLC purchased a new stake in Immunic in the 3rd quarter worth approximately $50,000. Finally, HB Wealth Management LLC bought a new stake in Immunic during the 4th quarter worth approximately $81,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.